BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17468190)

  • 1. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
    Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
    Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of parafibromin expression in a subset of parathyroid adenomas.
    Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
    Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
    Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
    Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
    Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
    J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
    Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
    Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
    Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
    Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.
    Woodard GE; Lin L; Zhang JH; Agarwal SK; Marx SJ; Simonds WF
    Oncogene; 2005 Feb; 24(7):1272-6. PubMed ID: 15580289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
    Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
    Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
    Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
    Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
    Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
    Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
    Wang O; Wang C; Nie M; Cui Q; Guan H; Jiang Y; Li M; Xia W; Meng X; Xing X
    PLoS One; 2012; 7(9):e45567. PubMed ID: 23029104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
    Juhlin CC; Nilsson IL; Johansson K; Haglund F; Villablanca A; Höög A; Larsson C
    Endocr Pathol; 2010 Sep; 21(3):166-77. PubMed ID: 20473645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HRPT2 gene analysis and the diagnosis of parathyroid carcinoma.
    Cetani F; Pardi E; Banti C; Borsari S; Ambrogini E; Vignali E; Cianferotti L; Viccica G; Pinchera A; Marcocci C
    Expert Rev Endocrinol Metab; 2008 May; 3(3):377-389. PubMed ID: 30754207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining a molecular phenotype for benign and malignant parathyroid tumors.
    Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
    Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.
    Sulaiman L; Haglund F; Hashemi J; Obara T; Nordenström J; Larsson C; Juhlin CC
    PLoS One; 2012; 7(9):e46325. PubMed ID: 23029479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
    Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
    Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.
    Kelly TG; Shattuck TM; Reyes-Mugica M; Stewart AF; Simonds WF; Udelsman R; Arnold A; Carpenter TO
    J Bone Miner Res; 2006 Oct; 21(10):1666-71. PubMed ID: 16995822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
    Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
    Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas.
    Haven CJ; van Puijenbroek M; Tan MH; Teh BT; Fleuren GJ; van Wezel T; Morreau H
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):370-6. PubMed ID: 17555500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.
    Shattuck TM; Välimäki S; Obara T; Gaz RD; Clark OH; Shoback D; Wierman ME; Tojo K; Robbins CM; Carpten JD; Farnebo LO; Larsson C; Arnold A
    N Engl J Med; 2003 Oct; 349(18):1722-9. PubMed ID: 14585940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.